CY1988A - Pharmaceutical compositions containing furan derivatives - Google Patents

Pharmaceutical compositions containing furan derivatives Download PDF

Info

Publication number: CY1988A
Authority: CY; Cyprus
Prior art keywords: composition; methyl; bismuth; ranitidine; salt
Prior art date: 1990-09-11

Application number

CY198897A

Other languages

English (en)

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-09-11

Filing date

1997-09-05

Publication date

1997-09-05

1997-09-05 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1997-09-05 Publication of CY1988A publication Critical patent/CY1988A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 7
150000002240 furans Chemical class 0.000 title 1
229960000620 ranitidine Drugs 0.000 claims abstract description 20
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims abstract description 16
229910052797 bismuth Inorganic materials 0.000 claims abstract description 15
150000003839 salts Chemical class 0.000 claims abstract description 14
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 12
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims abstract description 8
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 5
239000011975 tartaric acid Substances 0.000 claims abstract description 4
235000002906 tartaric acid Nutrition 0.000 claims abstract description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 34
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
159000000011 group IA salts Chemical class 0.000 claims description 14
229910000029 sodium carbonate Inorganic materials 0.000 claims description 14
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
-1 ranitidine bismuth carboxylate Chemical class 0.000 claims description 8
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
239000007892 solid unit dosage form Substances 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical group 0.000 claims description 2
LUOYFQVUYMMTRC-UHFFFAOYSA-N bismuth(3+) Chemical compound [Bi+3].[Bi+3] LUOYFQVUYMMTRC-UHFFFAOYSA-N 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
150000003841 chloride salts Chemical class 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 3
ANERHPOLUMFRDC-UHFFFAOYSA-K bismuth citrate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ANERHPOLUMFRDC-UHFFFAOYSA-K 0.000 claims 2
125000005587 carbonate group Chemical group 0.000 claims 1
229910052751 metal Inorganic materials 0.000 claims 1
239000002184 metal Substances 0.000 claims 1
150000001447 alkali salts Chemical class 0.000 abstract 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
239000004480 active ingredient Substances 0.000 description 22
239000003826 tablet Substances 0.000 description 22
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
235000019359 magnesium stearate Nutrition 0.000 description 16
239000001267 polyvinylpyrrolidone Substances 0.000 description 16
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 16
229920000036 polyvinylpyrrolidone Polymers 0.000 description 16
229920000168 Microcrystalline cellulose Polymers 0.000 description 9
239000008187 granular material Substances 0.000 description 9
239000008108 microcrystalline cellulose Substances 0.000 description 9
235000019813 microcrystalline cellulose Nutrition 0.000 description 9
229940016286 microcrystalline cellulose Drugs 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000008101 lactose Substances 0.000 description 7
238000007906 compression Methods 0.000 description 6
230000006835 compression Effects 0.000 description 6
239000000377 silicon dioxide Substances 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 3
229960004696 ranitidine bismuth citrate Drugs 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000590002 Helicobacter pylori Species 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
SULICOHAQXOMED-YDXPQRMKSA-H dibismuth;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Bi+3].[Bi+3].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O SULICOHAQXOMED-YDXPQRMKSA-H 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
208000011906 peptic ulcer disease Diseases 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
239000004254 Ammonium phosphate Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
229910000148 ammonium phosphate Inorganic materials 0.000 description 1
235000019289 ammonium phosphates Nutrition 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
XAUTYMZTJWXZHZ-UHFFFAOYSA-K bismuth;1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-UHFFFAOYSA-K 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BSGRLBPZSRZQOR-UHFFFAOYSA-N ethene-1,1-diamine Chemical compound NC(N)=C BSGRLBPZSRZQOR-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)
Saccharide Compounds (AREA)

CY198897A 1990-09-11 1997-09-05 Pharmaceutical compositions containing furan derivatives CY1988A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB909019875A GB9019875D0 (en)	1990-09-11	1990-09-11	Pharmaceutical compositions
NO920408A NO179694C (no)	1990-09-11	1992-01-30	Farmasöytiske preparater inneholdende ranitidinderivater
PCT/EP1992/000498 WO1993017679A1 (en)	1990-09-11	1992-03-05	Compositions containing ranitidine/bismuth carboxylates salts

Publications (1)

Publication Number	Publication Date
CY1988A true CY1988A (en)	1997-09-05

Family

ID=47884627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY198897A CY1988A (en)	1990-09-11	1997-09-05	Pharmaceutical compositions containing furan derivatives

Country Status (33)

Country	Link
US (1)	US5456925A (de)
EP (1)	EP0558779B1 (de)
JP (1)	JPH0692849A (de)
KR (1)	KR100196308B1 (de)
AT (2)	AT405134B (de)
AU (2)	AU640816B2 (de)
BE (1)	BE1005115A5 (de)
BG (1)	BG61931B1 (de)
CA (1)	CA2050970C (de)
CH (1)	CH683068A5 (de)
CY (1)	CY1988A (de)
DE (2)	DE4130061A1 (de)
DK (1)	DK159191A (de)
ES (1)	ES2072647T3 (de)
FI (1)	FI944047A7 (de)
FR (1)	FR2666508B1 (de)
GB (2)	GB9019875D0 (de)
HK (1)	HK60894A (de)
HU (1)	HU211846A9 (de)
IE (1)	IE65049B1 (de)
IL (1)	IL99428A (de)
IT (1)	IT1249696B (de)
MX (1)	MX9101009A (de)
NL (1)	NL194907C (de)
NO (1)	NO179694C (de)
NZ (1)	NZ239731A (de)
OA (1)	OA10093A (de)
RO (1)	RO112084B1 (de)
RU (1)	RU2108097C1 (de)
SE (1)	SE509694C2 (de)
SK (1)	SK279591B6 (de)
WO (1)	WO1993017679A1 (de)
ZA (1)	ZA917176B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9019875D0 (en) *	1990-09-11	1990-10-24	Glaxo Group Ltd	Pharmaceutical compositions
GB9120131D0 (en) *	1991-09-20	1991-11-06	Glaxo Group Ltd	Medicaments
DK0550083T3 (da) *	1991-12-06	1999-10-11	Glaxo Group Ltd	Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra
GB9127150D0 (en) *	1991-12-20	1992-02-19	Smithkline Beecham Plc	Novel treatment
JPH10512877A (ja) *	1995-01-26	1998-12-08	ニコムドイメージングエイ／エス	ビスマス化合物
GB9501560D0 (en) *	1995-01-26	1995-03-15	Nycomed Imaging As	Contrast agents
AU1513699A (en) *	1998-08-18	2000-03-14	Nikolai Borisovich Leonidov	Physically stable and x-ray amorphous form of hydrochloride ranitidine having anincreased antitumoral activity and method for producing the same
EP1104673A1 (de) *	1999-11-30	2001-06-06	Bayer Classics	Ein Hydrogencarbonat enthaltendes sprengmittelfreies Arzneimittel
KR100412290B1 (ko) *	2001-11-27	2003-12-31	주식회사 동구제약	라니티딘 함유 현탁제 조성물 및 그의 제조방법
US20060100271A1 (en) *	2004-11-08	2006-05-11	Keith Whitehead	Stabilized aqueous ranitidine compositions
EP2309988B1 (de) *	2008-07-21	2015-11-25	SI Group, Inc.	Granulat mit hohem ibuprofen-natriumgehalt, seine herstellung und seine verwendung bei der herstellung von nichtsprudelnden festen dosierformen
US9629809B2 (en)	2008-07-21	2017-04-25	Si Group, Inc.	High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
US20230218663A1 (en) *	2020-06-01	2023-07-13	The University Of Hong Kong	Compositions and methods for treating a sars-cov-2 infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4608257A (en) *	1984-01-03	1986-08-26	Board Of Regents For Oklahoma State University	Composition and method for treating heat stress
GB8629781D0 (en) *	1986-12-12	1987-01-21	Glaxo Group Ltd	Pharmaceutical compositions
DE3874917T2 (de) *	1987-03-09	1993-03-04	Procter & Gamble	Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
DE3710462A1 (de) *	1987-03-30	1988-10-13	Heumann Pharma Gmbh & Co	Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
FR2633181B1 (fr) *	1988-06-24	1992-01-10	Glaxo Lab Sa	Composition pharmaceutique a base de ranitidine et son procede de preparation
CH679582A5 (de) *	1988-07-18	1992-03-13	Glaxo Group Ltd
EP0363502B1 (de) *	1988-10-08	1991-09-25	Dr. R. Pfleger Chemische Fabrik Gmbh	Flüssiges, wismuthaltiges Arzneipräparat, Verfahren zum Herstellen desselben und seine Verwendung
AU641903B2 (en) *	1988-10-26	1993-10-07	Glaxo Group Limited	Carboxylic acid derivatives
US5013560A (en) *	1989-03-17	1991-05-07	The Procter & Gamble Company	Microbially-stable bismuth-containing liquid pharmaceutical suspensions
GB9019875D0 (en) *	1990-09-11	1990-10-24	Glaxo Group Ltd	Pharmaceutical compositions

1990
- 1990-09-11 GB GB909019875A patent/GB9019875D0/en active Pending
1991
- 1991-09-06 IL IL9942891A patent/IL99428A/en not_active IP Right Cessation
- 1991-09-09 CA CA002050970A patent/CA2050970C/en not_active Expired - Fee Related
- 1991-09-10 ZA ZA917176A patent/ZA917176B/xx unknown
- 1991-09-10 AT AT0180191A patent/AT405134B/de not_active IP Right Cessation
- 1991-09-10 BE BE9100841A patent/BE1005115A5/fr not_active IP Right Cessation
- 1991-09-10 IE IE319191A patent/IE65049B1/en not_active IP Right Cessation
- 1991-09-10 NZ NZ239731A patent/NZ239731A/en unknown
- 1991-09-10 JP JP3230571A patent/JPH0692849A/ja active Pending
- 1991-09-10 CH CH2655/91A patent/CH683068A5/fr not_active IP Right Cessation
- 1991-09-10 SE SE9102604A patent/SE509694C2/sv not_active IP Right Cessation
- 1991-09-10 KR KR1019910015760A patent/KR100196308B1/ko not_active Expired - Fee Related
- 1991-09-10 FR FR9111146A patent/FR2666508B1/fr not_active Expired - Fee Related
- 1991-09-10 GB GB9119284A patent/GB2248185B/en not_active Expired - Fee Related
- 1991-09-10 NL NL9101533A patent/NL194907C/nl not_active IP Right Cessation
- 1991-09-10 DE DE4130061A patent/DE4130061A1/de not_active Withdrawn
- 1991-09-10 DK DK159191A patent/DK159191A/da not_active Application Discontinuation
- 1991-09-10 IT ITRM910673A patent/IT1249696B/it active IP Right Grant
- 1991-09-10 AU AU83757/91A patent/AU640816B2/en not_active Ceased
1992
- 1992-01-30 NO NO920408A patent/NO179694C/no not_active IP Right Cessation
- 1992-03-05 RU RU94040869A patent/RU2108097C1/ru active
- 1992-03-05 MX MX9101009A patent/MX9101009A/es unknown
- 1992-03-05 AU AU13347/92A patent/AU1334792A/en not_active Abandoned
- 1992-03-05 AT AT92103741T patent/ATE122883T1/de not_active IP Right Cessation
- 1992-03-05 EP EP92103741A patent/EP0558779B1/de not_active Expired - Lifetime
- 1992-03-05 ES ES92103741T patent/ES2072647T3/es not_active Expired - Lifetime
- 1992-03-05 FI FI944047A patent/FI944047A7/fi unknown
- 1992-03-05 RO RO94-01459A patent/RO112084B1/ro unknown
- 1992-03-05 WO PCT/EP1992/000498 patent/WO1993017679A1/en not_active Ceased
- 1992-03-05 DE DE69202696T patent/DE69202696D1/de not_active Expired - Lifetime
- 1992-03-05 SK SK1060-94A patent/SK279591B6/sk unknown
1994
- 1994-03-22 US US08/215,658 patent/US5456925A/en not_active Expired - Lifetime
- 1994-06-23 HK HK60894A patent/HK60894A/xx not_active IP Right Cessation
- 1994-08-12 OA OA60553A patent/OA10093A/en unknown
- 1994-09-01 BG BG99021A patent/BG61931B1/bg unknown
1995
- 1995-06-28 HU HU95P/P00511P patent/HU211846A9/hu unknown
1997
- 1997-09-05 CY CY198897A patent/CY1988A/en unknown

Also Published As

Publication number	Publication date
BG61931B1 (bg)	1998-10-30
FI944047L (fi)	1994-09-02
HU211846A9 (en)	1995-12-28
NO920408L (no)	1993-08-02
SK106094A3 (en)	1995-02-08
IE913191A1 (en)	1992-04-22
MX9101009A (es)	1992-05-04
ES2072647T3 (es)	1995-07-16
AU640816B2 (en)	1993-09-02
NZ239731A (en)	1993-10-26
DK159191A (da)	1992-03-12
GB9119284D0 (en)	1991-10-23
IE65049B1 (en)	1995-10-04
ZA917176B (en)	1992-06-24
GB2248185A (en)	1992-04-01
AU8375791A (en)	1992-03-19
JPH0692849A (ja)	1994-04-05
DE69202696D1 (de)	1995-06-29
OA10093A (en)	1996-12-18
HK60894A (en)	1994-07-08
ITRM910673A1 (it)	1993-03-10
IT1249696B (it)	1995-03-09
NL194907C (nl)	2003-07-04
SE509694C2 (sv)	1999-02-22
RU2108097C1 (ru)	1998-04-10
RO112084B1 (ro)	1997-05-30
ATA180191A (de)	1998-10-15
DE4130061A1 (de)	1992-03-12
IL99428A0 (en)	1992-08-18
US5456925A (en)	1995-10-10
GB2248185B (en)	1994-02-02
NL194907B (nl)	2003-03-03
SE9102604L (sv)	1992-03-12
NO920408D0 (no)	1992-01-30
FR2666508B1 (fr)	1994-02-18
DK159191D0 (da)	1991-09-10
FI944047A0 (fi)	1994-09-02
CH683068A5 (fr)	1994-01-14
ITRM910673A0 (it)	1991-09-10
WO1993017679A1 (en)	1993-09-16
SK279591B6 (sk)	1999-01-11
AT405134B (de)	1999-05-25
NL9101533A (nl)	1992-04-01
CA2050970C (en)	2002-11-19
FI944047A7 (fi)	1994-09-02
EP0558779B1 (de)	1995-05-24
ATE122883T1 (de)	1995-06-15
SE9102604D0 (sv)	1991-09-10
BE1005115A5 (fr)	1993-04-27
GB9019875D0 (en)	1990-10-24
CA2050970A1 (en)	1992-03-12
KR100196308B1 (ko)	1999-06-15
NO179694B (no)	1996-08-26
IL99428A (en)	1996-06-18
EP0558779A1 (de)	1993-09-08
NO179694C (no)	1996-12-04
BG99021A (bg)	1995-06-30
KR920005984A (ko)	1992-04-27
FR2666508A1 (fr)	1992-03-13
AU1334792A (en)	1993-10-05

Publication	Publication Date	Title
US5814339A (en)	1998-09-29	Film coated tablet of paracetamol and domperidone
AU640816B2 (en)	1993-09-02	Pharmaceutical compositions containing furan derivatives
NZ505302A (en)	2001-12-21	Flash-melt dose comprising medicament, superdisintegrant, dispersing agent, distributing agent and binder
CA2000763C (en)	2000-11-14	Dispersable formulation
CY1637A (en)	1992-11-06	Pharmaceutical compositions
EP1165065B1 (de)	2003-05-07	Schluckbare tabletten mit einem hohen gehalt an n-acetylcystein
US5091191A (en)	1992-02-25	Pharmaceutical composition with improved dissolution property
JPS60163823A (ja)	1985-08-26	経口投与製剤
EP0814772B1 (de)	2001-07-18	Pharmazeutische zusammensetzungen mit pektin
CA1108992A (en)	1981-09-15	Pharmaceutical composition containing 1,3-bis(2- carboxychromon-5-yloxy)2-hydroxypropane
CZ209794A3 (en)	1994-12-15	Pharmaceutical preparation
HU217587B (hu)	2000-02-28	Ranitidint és bizmut-karboxilát-komplexet, valamint bázisos sókat tartalmazó gyógyászati készítmények
JPS63233919A (ja)	1988-09-29	薬学的組成物
NZ283354A (en)	1998-08-26	Oral pharmaceutical comprising low dosage amount of ranitidine as sole active ingredient for treating minor gastrointestinal disorders associated with excess acid secretion